Corbus Pharma (CRBP) Misses Q3 EPS by 4c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Corbus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
November 8, 2018 7:01 AM ESTLicensed Jenrin Discoverys extensive library of small molecules targeting the endocannabinoid system (ECS) positioning Corbus with the leading pipeline focused on treating inflammatory and fibrotic diseases through ECS pathwaysReported long-term open-label extension data from both Phase 2 systemic sclerosis and dermatomyositis studies showing maintenance of favorable safety profile and further improvement in multiple efficacy endpointsCompany to host conference call and webcast today, November 8, 2018, at 8:30 a.m. ET
Norwood, MA, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (Corbus or the... More
